BCAX (Bicara Therapeutics) Additional Paid-In Capital: $939.94 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BCAX Bicara Therapeutics Inc BCAX
14 GF Score
Price $22.80
! 3 Warning Signs
View Full Analysis

What is Bicara Therapeutics Additional Paid-In Capital?

Bicara Therapeutics BCAX -1.32% 14 Additional Paid-In Capital is $939.94 Mil as of Jun. 2026. GuruFocus rates BCAX with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.


Bicara Therapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($760.17 Mil) to Mar. 2026 ($929.37 Mil) and increased from Mar. 2026 ($929.37 Mil) to Jun. 2026 ($939.94 Mil).

Bicara Therapeutics's annual additional paid-in capital increased from Dec. 2023 ($4.25 Mil) to Dec. 2024 ($712.88 Mil) and increased from Dec. 2024 ($712.88 Mil) to Dec. 2025 ($760.17 Mil).

Bicara Therapeutics Additional Paid-In Capital Related Terms

Bicara Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for Bicara Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bicara Therapeutics Additional Paid-In Capital Chart

Bicara Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
2.23 4.25 712.88 760.17

Bicara Therapeutics Quarterly Data
Dec22 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 720.44 724.49 760.17 929.37 939.94
BCAX
14GF Score
Bicara Therapeutics Inc BCAX
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bicara Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $939.94 Mil mean?
Bicara Therapeutics (BCAX) has a Additional Paid-In Capital of $939.94 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Bicara Therapeutics and its competitors.
Is Bicara Therapeutics' Additional Paid-In Capital too high?
Bicara Therapeutics' current Additional Paid-In Capital is $939.94 Mil. Overall, Bicara Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Bicara Therapeutics' Additional Paid-In Capital compare to LTGO and LBRX?
Bicara Therapeutics' Additional Paid-In Capital of $939.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on Bicara Therapeutics and its competitors. Bicara Therapeutics's current Additional Paid-In Capital is $939.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bicara Therapeutics stock overvalued right now?
Bicara Therapeutics (BCAX) has a current Additional Paid-In Capital of $939.94 Mil. The current Additional Paid-In Capital is $939.94 Mil. Bicara Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For Bicara Therapeutics (BCAX), the current Additional Paid-In Capital is $939.94 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bicara Therapeutics Business Description

Address 116 Huntington Avenue, Suite 703, Boston, MA, USA, 02116
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b. The company's goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for people living with cancer, starting with ficerafusp alfa.
14GF Score

Get the complete analysis for BCAX

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$22.80
Price